GlassScriptPhysician profile
Michael E Hudack
NPI 1174712145
$1,616.40
in general payments reported to CMS, 2019-2025
19 companies · $685 in 2025
The $685 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $32.60 · 2023: $73.52 · 2024: $701 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.25 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $778.99 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $173.13 | 2024-2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $146.68 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $144.78 | 2024-2025 | Voquezna |
| Recordati_rare_diseases_inc. | $44.92 | 2024-2025 | Isturisa, Signifor Lar |
| Gilead Sciences, INC. | $42.84 | 2024-2025 | |
| Lundbeck LLC | $38.31 | 2024-2025 | Vyepti |
| Tanabe Pharma America, INC. | $33.90 | 2025 | Radicava |
| Alexion Pharmaceuticals, INC. | $33.19 | 2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $32.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.46 | 2025 | Eohilia |
| Celgene Corporation | $19.09 | 2023 | Reblozyl |
| Corcept Therapeutics | $17.73 | 2025 | Korlym |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Pfizer INC. | $14.69 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14.60 | 2024 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $14.30 | 2021 | |
| Neurelis, INC. | $14.17 | 2025 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $13.91 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hudack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.